Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Status:
Completed
Trial end date:
2017-05-18
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating
patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens
may help the body build an effective immune response to kill tumor cells. Giving epacadostat
with vaccine therapy may be an effective treatment for advanced melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
Incyte Corporation National Cancer Institute (NCI) University of Virginia